# FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition

> **NCT05937295** · PHASE1 · RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 20 (estimated)

## Conditions studied

- Fibrolamellar Hepatocellular Carcinoma

## Interventions

- **DRUG:** Fusion-VAC-XS15

## Key facts

- **NCT ID:** NCT05937295
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-26
- **Primary completion:** 2026-09
- **Final completion:** 2027-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05937295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05937295, "FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05937295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*